| __timestamp | Amneal Pharmaceuticals, Inc. | Apellis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 2908166 |
| Thursday, January 1, 2015 | 109679000 | 6356782 |
| Friday, January 1, 2016 | 118757000 | 4303743 |
| Sunday, January 1, 2017 | 109046000 | 10463151 |
| Monday, January 1, 2018 | 230435000 | 22639184 |
| Tuesday, January 1, 2019 | 289598000 | 67046483 |
| Wednesday, January 1, 2020 | 326727000 | 139401000 |
| Friday, January 1, 2021 | 365504000 | 176771000 |
| Saturday, January 1, 2022 | 399700000 | 277163000 |
| Sunday, January 1, 2023 | 429675000 | 500815000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, understanding the financial dynamics is crucial. Over the past decade, Amneal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, reflecting a strategic expansion and increased operational costs. In contrast, Apellis, starting with a modest base, witnessed an exponential rise, culminating in a 17,000% increase by 2023. This dramatic growth underscores Apellis's aggressive market penetration and investment in administrative capabilities. Notably, by 2023, Apellis's SG&A expenses surpassed Amneal's, highlighting a pivotal shift in financial strategy. These trends offer a window into the evolving priorities and market strategies of these pharmaceutical giants, providing valuable insights for investors and industry analysts alike.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Insmed Incorporated or Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights